GLP-1 drugs show promise beyond weight loss but come with digestive trade-offs

The drugs that have become synonymous with weight loss in recent years were never designed for that purpose. Glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, emerged from diabetes research, where they helped regulate blood sugar by mimicking a hormone the gut naturally produces after eating. They work by slowing stomach emptying, triggering earlier fullness, and signaling the pancreas to release insulin when needed. The weight loss came as a secondary effect—a consequence of eating less because the body felt satisfied sooner. Now that these medications have become household names, researchers are asking a harder question: what else are they actually doing to the body?

A sweeping review published in JAMA Network Open examined 1,751 randomized clinical trials involving more than 3.5 million participants to answer that question. The researchers cast a wide net, looking past the metabolic outcomes everyone already knew about—blood sugar control, weight reduction, heart and kidney function—and instead focused on what happens elsewhere. They found something consistent and unavoidable: gastrointestinal distress. Nausea, diarrhea, and vomiting appeared across study after study, a trade-off so reliable it emerged as the clearest signal in the data. For people taking these drugs, digestive side effects are not a rare occurrence but an expected part of treatment.

Yet the same review uncovered something unexpected. Buried in the evidence were hints of benefits that had nothing to do with weight or blood sugar. The drugs appeared to lower the risk of serious infections—a finding that surprised even the researchers, who cautioned that the mechanism remains unclear and the evidence remains preliminary. There were also suggestions that GLP-1 medications might protect lung health by reducing airway inflammation and oxidative stress, improvements that could be amplified by the weight loss itself, since shedding pounds often eases conditions like sleep apnea.

The brain emerged as another frontier. Some studies hinted that these drugs might offer protection against dementia, possibly through improved blood flow to neural tissue and reduced accumulation of harmful proteins. Bone health showed promise too—the medications could strengthen skeletal density and lower fracture risk, though researchers emphasized this finding remains less certain than others. Each of these potential benefits came with the same caveat: the evidence is exploratory, suggestive, not yet solid enough to guide clinical decisions.

What makes this review significant is not that it discovered anything revolutionary, but that it forced a reckoning with what we don't know. GLP-1 RAs have been studied extensively for their metabolic effects, but their broader impact on human health remains largely unmapped. As these drugs move from niche diabetes treatment to mainstream weight loss medication, millions of people are taking them without a complete picture of what they're getting. The gastrointestinal side effects are real and documented. The other potential benefits—the infection protection, the lung and brain and bone improvements—remain tantalizing possibilities that demand further investigation before doctors can responsibly recommend these drugs for anything beyond their established uses. The researchers made clear that before GLP-1s are considered as treatments for infections, respiratory disease, or cognitive decline, the evidence will need to be far more robust than what currently exists. For now, the drugs remain what they have always been: powerful tools with known drawbacks and unknown depths.